Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Globe Newswire (Thu, 24-Sep 7:00 AM ET)
Mesoblast Reports Substantial Revenue Growth to US$120M
Globe Newswire (Wed, 26-Aug 8:32 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Globe Newswire (Sun, 16-Aug 8:35 PM ET)
Globe Newswire (Wed, 29-Jul 8:57 PM ET)
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Globe Newswire (Mon, 13-Jul 8:35 PM ET)
Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Globe Newswire (Thu, 9-Jul 8:30 PM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Strong Ryoncil® Performance Drives Revenue Gains and Expands Mesoblast's Growth Pipeline
Market Chameleon (Fri, 27-Feb 3:44 AM ET)
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of October 6, 2026, MESO stock price declined to $13.80 with 174,552 million shares trading.
MESO has a beta of 1.72, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.16 to the broad based SPY ETF.
MESO has a market cap of $1.79 billion. This is considered a Small Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $120 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-61 million and exceeded earnings estimates by $.46.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, QQQS, IBBQ, BIB.
MESO has underperformed the market in the last year with a price return of -25.0% while the SPY ETF gained +17.9%. MESO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.0% and -10.9%, respectively, while the SPY returned +5.1% and +1.0%, respectively.
MESO support price is $13.81 and resistance is $14.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.
